10-Q: Alterola Biotech Reports Q1 2025 Results, Announces Merger with Chain Bridge I

Alterola Biotech, a pharmaceutical company, released its unaudited financial results for the quarter ended June 30, 2024, alongside announcing a business combination agreement with Chain Bridge I.

Summary

• Alterola Biotech reported a net loss of $419,298 for the three months ended June 30, 2024, compared to a net loss of $447,037 for the same period in 2023.
• The company's operating expenses decreased to $447,373 from $585,200 in the prior year, primarily due to lower consulting and director fees.
• As of June 30, 2024, Alterola had a working capital deficit of $1,495,669 and has incurred losses since inception of $12,835,373.
• The company has not generated any revenue since inception and expects to incur further losses in the development of its business.
• Alterola announced a business combination agreement with Chain Bridge I, a special purpose acquisition company, with the combined entity to be named Phytanix Inc. and listed on the Nasdaq Capital Market under the ticker symbol PHYX.
• The aggregate consideration for the business combination is derived from an equity value of $58 million.
• The transaction is expected to close in the fourth quarter of 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made some progress in reducing operating expenses and has secured a merger agreement, the ongoing losses, working capital deficit, and material weaknesses in internal controls are significant concerns. The sentiment is therefore cautiously negative.

Positives

• Operating expenses decreased year-over-year, indicating some cost control.
• The company has secured a business combination agreement that will provide access to public markets.

Negatives

• The company continues to operate at a loss and has a significant working capital deficit.
• Alterola has not generated any revenue since inception.
• The company has identified material weaknesses in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.
• There is no assurance that the company will be successful in raising additional funding.
• The company's disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• The business combination is subject to customary closing conditions, including shareholder approvals and Nasdaq listing approval.

Future Outlook

The company intends to fund operations through short-term or long-term debt and/or equity financing arrangements. The company expects that its operational expenses will increase significantly for the balance of the fiscal year ended March 31, 2025 and beyond. The business combination with Chain Bridge I is expected to close in the fourth quarter of 2024.

Management Comments

• Managements plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.
• Our goal is to provide better medicines for patients around the world. We believe in harnessing the therapeutic potential of cannabinoids and cannabinoidlike compounds, which can be developed into valuable treatments for seriously ill patients.

Industry Context

The announcement of the business combination reflects a trend of biotech companies seeking public market access through SPAC mergers. The company's focus on cannabinoid-based pharmaceuticals aligns with the growing interest in this sector.

Comparison to Industry Standards

• The company's lack of revenue and significant losses are not uncommon for early-stage biotech companies, particularly those focused on drug development.
• The company's operating expenses are relatively high compared to some other early-stage biotech companies, but this is likely due to the costs associated with research and development and regulatory compliance.
• The company's working capital deficit is a significant concern and highlights the need for additional financing.

Related Party Transactions

• A shareholder made advances to the company to fund operating expenses in the amount of $6,144.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential losses if the company is unable to secure additional financing or achieve profitability.
• Employees may be impacted by potential changes in the company's structure and operations following the merger.
• Customers and suppliers may experience changes in their relationships with the company as a result of the merger.

Next Steps

• The company plans to implement changes to enhance and improve the design of internal controls over financial reporting.
• The company will seek shareholder approval for the business combination with Chain Bridge I.
• The company will work to complete the business combination in the fourth quarter of 2024.

Key Dates

Keywords

biotech, pharmaceutical, cannabinoid, merger, acquisition, SPAC, Nasdaq, financial results, working capital, Phytanix